Evaluation of Efficacy A complete cytogenetic response, defined as the absence of Ph-positive metaphases, was determined based on G-banding in at least 20 cells in metaphase per bone marrow sample. Samples were collected within 6 weeks after randomization and every three months thereafter. If a sample had fewer than 20 cells in metaphase, the evaluation was repeated within four weeks. A confirmed comprehensive cytogenetic response by 12 months following the initiation of treatment was the primary end stage. A confirmed full cytogenetic response was defined as a full cytogenetic response documented on two consecutive assessments at least 28 days apart. Patients who had a first assessment of full cytogenetic response at 12 a few months that was confirmed on another assessment thereafter were considered to have had a confirmed complete cytogenetic response by 12 months.In general, the positioning of the discomfort had little effect on whether the patients reported their discomfort. The study found that chronic pain suffers who usually do not seek treatment tend to be younger men whose pain has much less impact on their usual actions. Other experts included Emmeline Watkins, Ph.D., from the Section of Epidemiology at AstraZeneca, and Peter Wollan, Ph.D., from Olmsted Medical Center, and Joseph Melton, M.D., from Mayo Clinic. The analysis was supported by a grant from AstraZeneca. A peer-review journal, Mayo Clinic Proceedings publishes original essays and reviews coping with scientific and laboratory medicine, clinical research, basic research research and medical epidemiology.